<p>Background: Small businesses are key participants in the growth at the Swedish market, partly for the labour opportunities, the technology and economic development. These companies should get resources to grow, both political and economic resources. The medtech companies in an introduction and expansion phase meet with problems concerning the financing of their growth. Key participants whom offer financing are Venture Capitalists.</p><p>Purpose: The purpose of this study is to examine Venture Capitalists demands on medtech companies in an introduction and expansion phase. A comparison between the demands and how well medtech companies achieve them will be done. In the event of occurring information and economic gap the study will elucidate the gaps.</p><p>Method: To gain such a encyclopaedic and just representation of the situation the authors carried through a combination of both quantitative and qualitative studies. The quantitative study got carried through by a questionnaire which got send by email to a number of medtech companies. The qualitative study was made up by interviews with three Venture Capitalists and three medtech companies.</p><p>Theory: To get at a greater understanding of the companies methods when obtaining capital, theories as the Pecking order, financial lifecycle and a third theory about which factors lead to small companies financial model, have been in used. And also a statement of a fourth theory, the financial gap, has been done. The theory describes an information asymmetry between the company and the financier. Models in use concerning the Venture Capitalists are constituted from their own documented claim surrounding financing.</p><p>Conclusion: The study indicates an occurrence of several factors that are important to obstruct the financial gap which accrue between medtech companies in early stages of their lifecycle and Venture Capitalists. The survey exhibit that Venture Capitalists are more willing to provide capital if a business angel already has invested in the company. A medtech company should seek itself to Venture Capitalists who have special qualification in life science because of their knowledge in the Medtech branch. Throughout the study we have realized that the younger a Medtech company is the less administrative it is. Therefore it should be important to impel a work as early as possible that involves more administration. Branch experts mention that it is important to increase clinical research and encouragement to fusion between companies to enlarge financing from Venture Capitalists.</p>

Background: Small businesses are key participants in the growth at the Swedish market, partly for the labour opportunities, the technology and economic development. These companies should get resources to grow, both political and economic resources. The medtech companies in an introduction and expansion phase meet with problems concerning the financing of their growth. Key participants whom offer financing are Venture Capitalists. Purpose: The purpose of this study is to examine Venture Capitalists demands on medtech companies in an introduction and expansion phase. A comparison between the demands and how well medtech companies achieve them will be done. In the event of occurring information and economic gap the study will elucidate the gaps. Method: To gain such a encyclopaedic and just representation of the situation the authors carried through a combination of both quantitative and qualitative studies. The quantitative study got carried through by a questionnaire which got send by email to a number of medtech companies. The qualitative study was made up by interviews with three Venture Capitalists and three medtech companies. Theory: To get at a greater understanding of the companies methods when obtaining capital, theories as the Pecking order, financial lifecycle and a third theory about which factors lead to small companies financial model, have been in used. And also a statement of a fourth theory, the financial gap, has been done. The theory describes an information asymmetry between the company and the financier. Models in use concerning the Venture Capitalists are constituted from their own documented claim surrounding financing. Conclusion: The study indicates an occurrence of several factors that are important to obstruct the financial gap which accrue between medtech companies in early stages of their lifecycle and Venture Capitalists. The survey exhibit that Venture Capitalists are more willing to provide capital if a business angel already has invested in the company. A medtech company should seek itself to Venture Capitalists who have special qualification in life science because of their knowledge in the Medtech branch. Throughout the study we have realized that the younger a Medtech company is the less administrative it is. Therefore it should be important to impel a work as early as possible that involves more administration. Branch experts mention that it is important to increase clinical research and encouragement to fusion between companies to enlarge financing from Venture Capitalists.

Health technology assessment (HTA) is a process that evaluates the value and effects of health technology during its life cycle and provides scientific information to decision makers. However, the chasm between healthcare and innovation has been highlighted in several research areas. HTA as a bridge connecting the research and decision-making demands, achieving more transparent processes and high quality of evidence to enable more effective and safer MedTech innovations to reach and benefit healthcare and patients. This thesis aims to examine the current status of HTA across different countries compared to Sweden to identify the major hurdles and enablers in this process and any opportunities for learning across systems. Germany, the United Kingdom, and Finland are three countries being compared to Sweden in the thesis. A literature review combined with interviews were the main methodologies used for this project. Peer-reviewed literature, government documents, and official websites gave an overview of the HTA systems in selected countries and laid a solid foundation for the more in-depth interviews. Eight interviews (nine interviewees) with HTA agencies and companies were performed via Zoom, along with an email communication(one interviewee) with Fimea. The interviews were used as a support tool to gain a better understanding of the whole HTA system. Some personal opinions were also helpful to gain a view of the system from an alternative, more practical perspective. The results show the different HTA processes and the evidence generation paths in four countries. Views from MedTech companies are also given. The HTA in Sweden has two main pathways: SBU and TLV. These two agencies have particular traits that work differently with distinct purposes. In terms of the evidence generation and assessment methods, they also share different points of view. It is difficult to simply compare these systems in parallel due to the system's complexity and different healthcare conditions in every country. But all countries, including Sweden, should realize the challenges ofthe existing HTA systems, and try to reduce the evidence generation gap between expectation and reality. This would create more opportunities for small MedTech companies to be involved in the process, and actively participate in international HTA cooperation. / Hälsoteknikutvärdering (HTA) är en process som utvärderar värdet och effekterna avhälsoteknik i dess livscykel och ger vetenskaplig information till beslutsfattare. Klyftanmellan hälso- och sjukvård och innovation har dock lyfts fram inom fleraforskningsområden. HTA länkar forskning och beslutsfattande genom att möjliggöramer transparenta processer och hög kvalitet på bevis för effektivare och säkrareMedTech-innovationer att nå och gynna sjukvård och patienter. Denna uppsats syftartill att undersöka HTA:s nuvarande status i olika länder jämfört med Sverige för attidentifiera de största hindren och möjliggörare i denna process och eventuellamöjligheter till lärande i olika system. Tyskland, Storbritannien och Finland är treländer som jämförs med Sverige i avhandlingen. Litteraturöversikt och intervjuer är de huvudsakliga metoderna som används för dettaprojekt. Forskargransakad litteratur, regeringsdokument och officiella webbplatser gaven översikt över HTA-systemen i utvalda länder och lade en solid grund för följandeintervjuer. Åtta intervjuer (nio intervjuade) med HTA-byråer och MedTech-företaggenomfördes via Zoom, tillsammans med en e-postkommunikation med Fimea.Intervjuerna användes som ett stödverktyg för att ge en bättre förståelse för hela HTAsystemet.Vissa personliga åsikter gav tillfälle att förstå HTA från ett alternativtperspektiv jämfört med dess beskrivning i litteraturen. Resultaten visar olika HTA-processer och bevisgenereringsvägar i fyra länder, samtsynpunkter från MedTech-företag. HTA i Sverige har två huvudvägar: SBU (viaregionala HTA centra) och TLV. Dessa två vägar har speciella egenskaper som fungerarannorlunda och med olika syften. När det gäller bevisgenerering ochbedömningsmetoder skiljs de även åt. Det är utmanande att jämföra dessa systemparallellt på grund av systemets komplexitet och olika sjukvårdsförhållanden i varjeland. Men alla länder, inklusive Sverige, bör inse brister i befintlig HTA och försökaminska bevisgenereringsgapet mellan förväntan och verkligheten. Under tiden skapasfler möjligheter för små MedTech-företag att delta i processen och delta aktivt iinternationella HTA-samarbeten.